title: Self-assembling doxorubicin silk hydrogels for the focal treatment of primary breast cancer.
abstract: Standard care for early stage breast cancer includes tumor resection and local radiotherapy to achieve long-term remission. Systemic chemotherapy provides only low locoregional control of the disease; therefore, we describe self-assembling silk hydrogels that can retain and then deliver doxorubicin locally. Self-assembling silk hydrogels show no swelling, are readily loaded with doxorubicin under aqueous conditions and release drug over 4 weeks in amounts that can be fine-tuned by varying the silk content. Following successfulin vitrostudies, locally injected silk hydrogels loaded with doxorubicin show excellent antitumor response in mice, outperforming the equivalent amount of doxorubicin delivered intravenously. In addition to reducing primary tumor growth, doxorubicin-loaded silk hydrogels reduce metastatic spread and are well toleratedin vivo. Thus, silk hydrogels are well suited for the local delivery of chemotherapy and provide a promising approach to improve locoregional control of breast cancer.
authors: Tufts University, Department of Biomedical Engineering, 4 Colby Street, Medford, MA 02155, USA.
authors: F Philipp
authors: FP
authors: Seib
authors: Eleanor M
authors: EM
authors: Pritchard
authors: David L
authors: DL
authors: Kaplan
keywords: Cancer; Silk hydrogel; adriamycin; drug delivery
references: Biomaterials. 2008 Mar;29(8):1054-64
references: 18031805
references: Nat Protoc. 2011 Sep 22;6(10):1612-31
references: 21959241
references: Biophys J. 2009 Oct 7;97(7):2044-50
references: 19804736
references: J Control Release. 2010 Jun 15;144(3):280-7
references: 20184934
references: N Engl J Med. 2002 Oct 17;347(16):1233-41
references: 12393820
references: Biomaterials. 2010 Nov;31(31):8051-62
references: 20696470
references: Cancer Res. 2010 Dec 15;70(24):10044-50
references: 21159629
references: J Control Release. 2010 Feb 25;142(1):101-7
references: 19819274
references: Clin Chim Acta. 2003 Mar;329(1-2):39-51
references: 12589964
references: Acta Neurochir (Wien). 2006 Mar;148(3):269-75; discussion 275
references: 16482400
references: Lancet. 1995 Apr 22;345(8956):1008-12
references: 7723496
references: J Clin Invest. 1981 Oct;68(4):1053-64
references: 7287901
references: Semin Oncol. 1992 Dec;19(6):670-86
references: 1462166
references: Biomaterials. 1982 Jul;3(3):150-4
references: 7115858
references: Expert Opin Drug Deliv. 2011 Jun;8(6):797-811
references: 21453189
references: Ann Intern Med. 1996 Jul 1;125(1):47-58
references: 8644988
references: Food Chem Toxicol. 2009 Jul;47(7):1538-44
references: 19358873
references: Science. 2010 Jul 30;329(5991):528-31
references: 20671180
references: Biomaterials. 2012 Mar;33(7):2272-81
references: 22177840
references: Biomed Pharmacother. 2011 Oct;65(7):481-5
references: 22000485
references: Int J Pharm. 2011 May 30;410(1-2):83-91
references: 21421032
references: N Engl J Med. 1997 Oct 2;337(14):949-55
references: 9395428
references: Biomacromolecules. 2011 Mar 14;12(3):804-12
references: 21250666
references: J Control Release. 2011 Mar 10;150(2):128-41
references: 21059377
references: J Control Release. 2011 Nov 30;156(1):21-7
references: 21777632
references: Prog Polym Sci. 2007;32(8-9):991-1007
references: 19543442
references: N Engl J Med. 2002 Oct 17;347(16):1227-32
references: 12393819
references: Cell. 2006 Nov 17;127(4):679-95
references: 17110329